interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease

Sarcoma, Soft Tissue

Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease

anlotinib

Liaoning Province Tumor Hospital

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Locally Recurrent or Metastatic Soft Tissue Sarcoma Patients: a One-arm, Multi-center, Prospective Clinical Trial

Progress free survival (PFS) defined as the time from first dose of study treatment until the first date of either objective disease progression or death due to any cause.

Overall Survival (OS) is defined as the time until death due to any cause.

Objective Response Rate (ORR) is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy.

Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.

Number of Participants with Adverse Events and Clinical laboratory numerical evaluation as a Measure of Safety.

Liaoning Tumor Hospital & Institute

First Hospital of China Medical University

Dalian Municipal Central Hospital

The Second Affiliated Hospital of Dalian Medical University

China-Japan Friendship Hospital

The Third Affiliated Hospital of Harbin Medical University

Second Hospital of Jilin University

Daqing Oil Field Hospital

Dermatofibrosarcomas of DARIER FERRAND(DFSP)

Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.

Pazopanib

Hôpital Saint-Louis - Service de Dermatologie (Pole POPS)

Phase II Pazopanib Study in Advanced Dermatofibrosarcomas

A Phase IIa Open Multicenter, Trial, of Treatment With Pazopanib (Multi Tyrosine Kinase Inhibitor) in Dermatofibrosarcomas (DFSP), Unresectable Locally Advanced (Potentially Mutilating Surgery), Primary or Relapsing , Transformed or Not.

tyrosinase/саркома

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

Phase II Pazopanib Study in Advanced Dermatofibrosarcomas

Самая полная база данных о лекарственных травах, подтвержденная наукой